Scynexis posts $1.2M loss in first earnings release since IPO

Posted by John Murawski on June 19, 2014 

Durham drug developer Scynexis posted a $1.2 million loss this week in the company’s first earnings release since its public stock offering last month.

The 90-employee company’s first-quarter loss compares to a loss of $2.1 million in the first quarter a year ago.

Scynexis, which spun out of Aventis in 2000, does not have a drug on the market. It’s developing SCY-078, a treatment for serious and life-threatening fungal infections.

The experimental drug stemmed from a collaboration between Scynexis and pharmaceutical giant Merck. Last year Merck returned the development and commercialization rights to Scynexis.

The company posted first quarter revenue of $1.8 million, same as a year earlier. The money was generated from R&D contract work for other companies.

Scynexis’s focus for the rest of 2014 will be developing an oral and intravenous formulation of SCY-078.

Its shares were at $9.77 in midday trading, up 13 cents. The company’s shares began trading at $10 last month.

News & Observer is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Commenting FAQs | Terms of Service